пятница, 16 декабря 2016 г.

UPDATE 4-Lilly eases investors' jitters with strong 2017 forecast

UPDATE 4-Lilly eases investors' jitters with strong 2017 forecast


Eli Lilly and Co, in a move that appeared to ease investor concerns after the failure of its high-profile Alzheimer's drug, on Thursday provided a 2017 forecast above Wall Street estimates and expressed confidence in recently launched products and those in development. The company issued the upbeat outlook following profound investor disappointment last month, when the Alzheimer's drug solanezumab failed to slow mental declines of patients with even mild symptoms, dashing most hopes for a treatment that, if successful, would have been a multibillion-dollar seller.



from Biotech News